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Abstract
Background: The prognostic value of rectal invasion is still unclear in stage IVA cervical cancer. The objective of
this study is to evaluate patient outcome and prognostic factors in stage IVA cervical cancer treated with radiation
therapy.
Methods: A retrospective review of the medical records of patients treated with definitive photon radiation therapy
for pathologically proven stage IVA cervical cancer between 1980 and 2010 was performed. Eligible patients for the
present study were diagnosed with clinical stage IVA cervical cancer by cystoscopy or/and proctoscopy, and they
received definitive radiation therapy consisting of a combination of external beam radiotherapy and high-dose-rate
brachytherapy. All patients underwent CT scans of the abdomen and pelvis.
Results: Among the 67 stage IVA patients studied, 53 patients were stage IVA on the basis of bladder invasion, 7
according to rectal mucosal invasion, and 7 because of both bladder and rectal mucosal invasion. Median follow-up
of all patients and surviving patients was 19 months (range, 2–235 months) and 114 months (range, 14–223 months),
respectively. The 5-year local control (LC), disease-free survival (DFS), and overall survival (OS) rate were 55, 17, and 24 %,
respectively. Rectal invasion had significant impact on DFS, but bladder invasion had the opposite effect (p = 0.00006
and 0.005, respectively). There were significant differences of LC, DFS and OS rates between patients with and without
rectal invasion (p = 0.006, 0.00006 and 0.05, respectively).
Conclusions: Patients with stage IVA cervical cancer had poor prognosis, with 5-year survival of only 24 %. Furthermore,
in stage IVA, rectal invasion might be a worse prognostic factor than bladder invasion.
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Background
The combination of external beam radiotherapy and intra-
cavitary brachytherapy is considered one of the standard
treatments for locally advanced uterine cervical cancer.
Stage IVA cervical cancer is defined by the International
Federation of Gynecology and Obstetrics (FIGO) and
Union for International Cancer Control as a disease dir-
ectly invading the mucosa of the bladder and/or rectum.
There are limited reports on the clinical results for FIGO
stage IVA cervical cancer because it represents a small
subset of cervical cancer patients, with estimates only
around 3.1 % [1]. Three- or five-year overall survival rates
for stage IVA disease were reported to be between 21 and
48 % [2–5], and their prognosis is poorer than FIGO II or
III disease [3, 6].
On the other hand, according to previous reports in the
literature, most of the stage IVA patients were diagnosed
based on bladder invasion, and only 1 to 4 patients in any
of the studies had rectal invasion [2, 4, 5, 7]. Therefore, the
prognostic value of rectal invasion in stage IVA cervical
cancer is still unclear. The objective of this study is to
evaluate patient outcome and prognostic factors in stage
IVA cervical cancer treated with the combination of exter-
nal beam radiotherapy and intracavitary brachytherapy.
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This retrospective review was performed using the medical
records of patients treated with definitive photon radiation
therapy for pathologically proven primary invasive cervical
cancer at the National Institute of Radiological Sciences,
Chiba, Japan, between 1980 and 2010. The eligible patients
for the present study were diagnosed with clinical stage
IVA cervical cancer by cystoscopy or/and proctoscopy, and
biopsy of the bladder or rectal growth was performed for
confirmation of stage IVA disease if possible. They received
definitive radiation therapy consisting of the combination
of external beam radiotherapy and high-dose-rate (HDR)
brachytherapy. None of the patients had undergone any
surgical procedures including pelvic lymphadenectomy.
Pretreatment evaluation was comprised of an assessment
of the patient’s history, physical and pelvic examinations by
gynecologists and radiation oncologists, cervical biopsy,
routine blood cell counts, chemistry profile, chest X-ray,
and computed tomography (CT) scans of the abdomen
and pelvis. Magnetic resonance imaging (MRI) scans of the
pelvis have been performed since 1993. Median age of the
patients was 70 years (range, 38–87 years). All patients
were staged according to the FIGO staging system, but pa-
tients with para-aortic lymph nodes ≥ 1 cm in minimum
diameter on CT images were excluded from the study,
although patients with enlarged pelvic lymph nodes only
were included. The criterion for pelvic lymph node en-
largement was ≥ 1 cm diameter on CT images. Cervical
tumor size was determined from clinical descriptions,
tumor diagrams, CT images and MRI (if available), and
was classified into 2 categories (≤6 cm, > 6 cm). A total of
67 patients were admitted to this retrospective analysis.
This study was approved by the Ethics Committee of
Human Clinical Research of the National Institute of
Radiological Sciences in March of 2015, and according to
the Declaration of Helsinki in its revised version. The need
for informed consent was waived by the Ethics Committee
of Human Clinical Research of the National Institute of
Radiological Sciences because this study was non-invasive
and was based on only medical records.
Treatment
Radiation therapy
Patients were treated with a combination of external
beam irradiation and HDR intracavitary brachytherapy
or interstitial brachytherapy. External irradiation was
delivered with 10 MV photons by using antero-
posterior and postero-anterior parallel opposing ports
or four-field technique. The common whole pelvic
field borders were at the interspace of the L4–5 ver-
tebrae superiorly, at the inferior border of the obtur-
ator foramen inferiorly, and at 1.5–2 cm lateral to the
bony pelvis. After start of brachytherapy, a central
shield was used in the whole pelvic fields. The frac-
tion of external irradiation was mostly 1.8 – 2 Gy
midplane tumor-dose daily, four to five fractions
weekly to the pelvic lesion. Doses to the whole pelvic
fields ranged from 24.0 to 54.0 Gy (median 40.0 Gy),
and doses to the total pelvis, consisting of the com-
bined doses to the whole pelvic and central shielding
fields, ranged from 44.0 to 61 Gy (median 50.0 Gy).
After whole pelvic irradiation, HDR intracavitary
brachytherapy by remote afterloading system using
iridium-192 or cobalt-60 source was performed.
Source arrangement, irradiation conditions, and dose
distribution were based on the Manchester system.
Point A was defined on X-ray as being 2 cm superior
to the external os, and 2 cm lateral from the axis of
the intrauterine tandem. HDR brachytherapy was per-
formed at 1 fraction a week, with a standard prescribed
dose to Point A of 5–7 Gy per fraction, for a total dose of
1–5 fractions (median: 4 fractions).
Table 1 Patient and disease characteristics (n = 67)
Characteristics No.
Age, y, median (range) 70 (38–87)
Bladder or rectal invasion
Bladder only 53 (79.1 %)
Rectal only 7 (10.4 %)
Both bladder and rectal 7 (10.4 %)
Parametrium invasion
To pelvic wall 59 (88.1 %)
Not to pelvic wall 8 (11.9 %)
Vaginal invasion
To lower third 20 (29.9 %)
Not to lower third 47 (70.1 %)
Hydronephrosis
Yes 32 (47.8 %)
No 35 (52.2 %)
Pelvic lymph node enlargement
Yes 27 (40.3 %)
No 40 (59.7 %)
Concurrent chemotherapy
Yes (CCRT) 11 (16.4 %)
No (radiation therapy alone) 56 (83.6 %)
Histology
Squamous cell carcinoma 61 (91.0 %)
Adenocarcinoma 6 (9.0 %)
Tumor size
≤6 cm 22 (32.8 %)
>6 cm 45 (67.2 %)
Wakatsuki et al. BMC Cancer  (2016) 16:244 Page 2 of 7
Chemotherapy
In our facility, since 2002 the treatment policy for locally
advanced cervical cancer has been concurrent chemo-
therapy (CCRT) with a chemotherapy regimen of weekly
cisplatin (40 mg/m2/week). Concurrent chemoradiother-
apy was not performed in patients with insufficient renal
function or age over 70 years, so 5 of 17 patients re-
ceived CCRT after 2002. On the other hand, most of the
patients received radiotherapy alone until 2001, and 6 of
52 patients received CCRT with a chemotherapy regi-
men of bleomycin or peplomycin and mitomycin C.
Among all patients, 56 (84 %) were treated by radiother-
apy alone and 11 (16 %) by CCRT as well.
Follow-up
After completion of radiotherapy, patients were followed
up every 1–3 months for 2 years, and every 3 or 6 months
thereafter. The procedures consisted of a physical examin-
ation, routine blood cell counts, chemistry profile, chest
X-ray, and CT scan. Suspected persistent or recurrent dis-
ease was confirmed by biopsy whenever possible.
Statistical analysis
Time to recurrence was measured from the date of the
start of treatment. The Kaplan-Meier method was used
to derive estimates of overall survival (OS), local control
(LC) and disease-free survival (DFS) rates. Prognostic
values were compared by DFS because the data for this
study were from 1980 to 2010, and salvage treatment
after recurrence had improved during these 30 years.
Prognostic values for DFS were investigated by log-
rank test. Age (≥70 years or < 70 years), tumor size
(>6 cm or ≤ 6 cm), rectal invasion (yes or no), bladder
invasion (yes or no), parametrium invasion (to pelvic
wall or not), vaginal invasion (lower third or not), hydro-
nephrosis (yes or no), pelvic lymph node enlargement
(yes or no), concurrent chemotherapy (yes or no), histo-
logical type (squamous cell carcinoma or adenocarcinoma)
were considered binary variables. Log-rank test was used
for statistical analyses of the differences of DFS, LC and
OS between the patients with and without rectal invasion.
Statistical significance was defined as a P value of < 0.05.
All statistical analyses were performed using SPSS Statistics
version 18.0 (SAS Institute, Tokyo, Japan).
Results and discussion
Sixty-seven patients with stage IVA were diagnosed and
given definitive radiation therapy during this 30-year
period at our institution. Patient characteristics are pre-
sented in Table 1. Fifty-three patients were stage IVA on
the basis of bladder invasion, seven on the basis of rectal
mucosal invasion, and seven on the basis of both bladder
and rectal mucosal invasion. The median follow-up dur-
ation for all patients and surviving patients was 19 months
(range, 2–235 months) and 114 months (range, 14–223
months), respectively. Median duration of treatment was
49 days (range, 25 – 59 days). That in patients with and
without rectal invasion was 49 days (range, 25 – 59 days)
and 49 days (range, 30 – 57 days), respectively. Median
total dose of external beam irradiation and HDR brachy-
therapy with and without central shielding fields along with
BED was 91.8 Gy10 (range, 68.3 – 117.1 Gy10) and
74.4 Gy10 (range, 56.3 – 105.1 Gy10), respectively. That
Fig. 1 Disease-free survival, local control and overall survival curves; disease-free survival (green line), local control (blue line), and overall survival
curves (red line) are shown for all patients
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without central shielding fields in patients with and without
rectal invasion was 74.4 Gy10, (range, 45.3 – 105.1 Gy10)
and 76.1 Gy10, (range, 56.3 – 90.6 Gy10), respectively.
The LC, DFS and OS curves of all patients are shown
in Fig. 1. The 5-year LC, DFS, and OS rates were 55, 17,
and 24 %, respectively, and the 2-year LC, DFS, and OS
rates were 55, 19, and 35 %, respectively. A comparison
of prognostic factors for DFS in stage IVA cervical can-
cer patients is shown in Table 2. Rectal invasion, vaginal
invasion, hydronephrosis and pelvic lymph node enlarge-
ment showed statistically significant consequences on
DFS, while bladder invasion had an opposite effect
(Table 2). The patient characteristics with and without
rectal invasion are shown in Table 3. The patient group
with rectal invasion had a significantly higher rate of
lymph node enlargement.
DFS, LC and OS curves of the patients with and with-
out rectal invasion are shown in Figs. 2, 3 and 4, respect-
ively. All patients without rectal invasion had bladder
invasion. There were significant differences of DFS, LC,
and OS among the groups (p = 0.00006, 0.006 and 0.05,
respectively). The 2-year DFS, LC, and OS rates of the
patients without rectal invasion were 24, 61, and 39 %,
respectively. Those of the patients with rectal invasion
were 0, 32, and 21 %, respectively. No patient with rectal
invasion survived over 4 years.
The numbers of observed Grade 2 or higher late com-
plications are listed in Table 4. Seven of 67 patients
showed late complications of the bladder, 3 of the
Table 2 Comparison of prognostic factors for disease-free sur-
vival in stage IVA cervical cancer patients






Yes 14 3.6 0 0.00006
No 53 13.3 23.6
Bladder invasion
Yes 60 11.0 20.9 0.005
No 7 3.4 0
Parametrium invasion
To pelvic wall 59 11.0 16.0 0.957
Not to pelvic wall 8 2.4 37.5
Vaginal invasion
To pelvic wall 20 5.0 10.0 0.025
Not to pelvic wall 47 12.7 22.4
Hydronephrosis
Yes 32 9.0 7.1 0.033
No 35 11.0 28.6
Pelvic lymph node enlargement
Yes 27 7.1 11.1 0.036
No 40 13.3 23.7
Concurrent chemotherapy
Yes 11 8.7 9.1 0.272




61 11.0 17.2 0.726
Adenocarcinoma 6 2.6 33.3
Tumor size
≤6 cm 22 6.5 27.3 0.689
>6 cm 45 11.0 14.2
Table 3 Patient characteristics with and without rectal invasion
Characteristics Rectal
invasion
No rectal invasion (Bladder
invasion only)
P value
(N = 14) (N = 53)
Age, y, median
(range)
69 (38–80) 71 (38–87) 0.277
Bladder invasion
Yes 7 (50 %) 53 (100 %) 0.000001
No 7 (50 %) 0
Parametrium invasion
To pelvic wall 14
(100 %)
45 (84.9 %) 0.278
Not to pelvic wall 0 8 (15.1 %)
Vaginal invasion
To lower third 6 (42.9 %) 14 (26.4 %) 0.386
Not to lower
third
8 (57.1 %) 39 (73.6 %)
Hydronephrosis
Yes 7 (50 %) 25 (47.2 %) 0.911
No 7 (50 %) 28 (52.8 %)
Pelvic lymph node enlargement
Yes 10
(71.4 %)
17 (32.1 %) 0.018
No 4 (28.6 %) 36 (67.9 %)
Concurrent chemotherapy
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rectosigmoid colon, and 3 of the small intestine. One pa-
tient developed excised perforated intestine or sigmoid
colon and vesicovaginal fistula and one patient devel-
oped vesicovaginal fistula.
Discussion
To the best of our knowledge, this is the first report of
the analysis of the prognostic value of rectal invasion.
The present study revealed that rectal invasion might be
a worse prognostic factor than bladder invasion in Stage
IVA cervical cancer after radiation therapy. Rectal inva-
sion, vaginal invasion, hydronephrosis and pelvic lymph
node enlargement showed statistically significant effects
on DFS in these patients.
Rectal invasion might be a worse prognostic factor
than bladder invasion in Stage IVA cervical cancer
after radiation therapy. Several researchers reported
that the 3-year or 5-year overall survival rates for
stage IVA disease were between 21 and 48 % [2–5],
although those studies each included only 1 to 4
patients with rectal invasion. In the present study, the
5-year survival rate of patients without rectal invasion
was 30 %, a result similar to other reports. However,
no patient with rectal invasion survived over 4 years,
and rectal invasion showed a significant impact on
DFS, as opposed to bladder invasion. DFS differed
significantly between patients with and without rectal
invasion (p = 0.0008). Thus, in Stage IVA cervical
Fig. 2 Disease-free survival curves of patients with and without rectal invasion; those of patients with rectal invasion (red line) and without rectal
invasion (blue line) are shown
Fig. 3 Local control curves of patients with and without rectal invasion; those of patients with rectal invasion (red line) and without rectal invasion
(blue line) are shown
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cancer, rectal invasion appears to be a poorer prog-
nostic factor than bladder invasion.
Rose et al. and Logsdon et al. reported the significance
of hydronephrosis on the outcome of patients with stage
IIIB cervical cancer treated with radiation therapy [8, 9].
Cervical cancer extending to the lower third of the vagina
has been considered as a factor involved in treatment fail-
ure. Kavadi et al. reported that the 5-year survival rate of
patients with lower-third vaginal involvement in patients
with stage IIIB cervical cancer was only 25 % [10]. Logs-
don et al. also reported that poor disease-specific survival
was correlated with involvement of the lower third of the
vagina [9]. These reports concluded that hydronephrosis
and involvement of the lower third of the vagina were
poor prognostic factors in patients with stage IIIB cervical
cancer. In addition, it is well known that pelvic lymph
node enlargement is one of the significant prognostic fac-
tors in cervical cancer patients [11, 12]. In the present
study, hydronephrosis, involvement of the lower third of
the vagina, and pelvic lymph node enlargement showed
statistically significant consequences for DFS. Thus, these
factors will be poor prognostic factors in patients with
stage IVA cervical cancer.
In the current study, 31 % of the patients with bladder
invasion and without rectal invasion showed 5 years or
longer survival, but no patients with rectal invasion
reached 4-year survival, as they all developed local or/
and distant failure within 18 months. Therefore, concur-
rent or adjuvant chemotherapy will be expected to im-
prove the treatment outcome for such patients. Since
2001, on the basis of several randomized trials, the
standard treatment for locally advanced cervical cancer,
including stage IVA patients, has been CCRT [13–16].
However, there were no significant differences in DFS
between patients receiving CCRT and radiation therapy
alone in this study. This was obviously related to the fact
that only 16 % of the patients received CCRT, as this ana-
lysis included the patients before 2000, half of the patients
were elderly (median age was 70 years), and many patients
had insufficient renal function due to hydronephrosis.
Therefore, new treatment techniques, such as intensity-
modulated radiation therapy [17], image-guided brachy-
therapy [18, 19] and carbon ion radiotherapy [20, 21], are
expected to improve the treatment outcome of stage IVA
cervical cancer.
Conclusions
The 5-year survival rate of patients with stage IVA dis-
ease was only 24 %, so the prognosis was poor. Further-
more, for this group of patients, rectal invasion with or
without bladder invasion was a worse prognostic factor
than bladder invasion alone in stage IVA. Thus, these
patients are in need of even more aggressive therapy.
Abbreviations
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HDR: high-dose-rate; LC: local control; MRI: magnetic resonance imaging;
OS: overall survival.
Fig. 4 Overall survival curves of patients with and without rectal invasion; those of patients with rectal invasion (red line) and without rectal invasion
(blue line) are shown
Table 4 Grade 2 or higher late complications by RTOG/EORTC
scoring scheme
No. G2 G3 G4-5
Rect/Sigmoid 67 1 1 1
Bladder 67 4 1 2
Small intestine 67 1 1 1
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